Black Hawk Acquisition (BKHA) vs eXoZymes (EXOZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($51.1 million vs $49.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BKHA | EXOZ |
|---|---|---|
| Share price | $12.30 | $5.33 |
| Market cap | $51.09M | $49.59M |
| 1-day change | -5.38% | -3.79% |
| YTD return | — | -49.17% |
| 1-year return | — | -58.96% |
| P/E ratio (TTM) | 37.27 | — |
| EPS (TTM) | $0.33 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $18.40 |
| 52-week low | $11.00 | $4.35 |
| Distance from 52-week high | -6.46% | -71.03% |
| Average volume | 3.63K | 6.80K |
| Shares outstanding | 4.15M | 9.30M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
BKHA vs EXOZ FAQ
Which is bigger, Black Hawk Acquisition or eXoZymes?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $51.09M compared with $49.59M for eXoZymes (EXOZ).
Are Black Hawk Acquisition and eXoZymes in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.